NASDAQ:ACRV Acrivon Therapeutics (ACRV) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free ACRV Stock Alerts $7.15 +0.69 (+10.68%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$6.01▼$7.3050-Day Range$3.40▼$7.1552-Week Range$3.19▼$14.39Volume127,890 shsAverage Volume76,782 shsMarket Capitalization$158.66 millionP/E RatioN/ADividend YieldN/APrice Target$22.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Acrivon Therapeutics alerts: Email Address Acrivon Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside209.7% Upside$22.14 Price TargetShort InterestBearish4.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.18Based on 13 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.63) to ($2.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.94 out of 5 starsMedical Sector640th out of 938 stocksPharmaceutical Preparations Industry287th out of 417 stocks 3.5 Analyst's Opinion Consensus RatingAcrivon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.14, Acrivon Therapeutics has a forecasted upside of 209.7% from its current price of $7.15.Amount of Analyst CoverageAcrivon Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.04% of the float of Acrivon Therapeutics has been sold short.Short Interest Ratio / Days to CoverAcrivon Therapeutics has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Acrivon Therapeutics has recently increased by 22.66%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcrivon Therapeutics does not currently pay a dividend.Dividend GrowthAcrivon Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACRV. Previous Next 2.3 News and Social Media Coverage News SentimentAcrivon Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Acrivon Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ACRV on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows3 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acrivon Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.30% of the stock of Acrivon Therapeutics is held by insiders.Percentage Held by Institutions71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acrivon Therapeutics are expected to decrease in the coming year, from ($2.63) to ($2.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acrivon Therapeutics is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acrivon Therapeutics is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcrivon Therapeutics has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here About Acrivon Therapeutics Stock (NASDAQ:ACRV)Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.Read More ACRV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACRV Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV)March 29, 2024 | markets.businessinsider.comBuy Rating Justified by Acrivon Therapeutics’ Clinical Progress and Market PotentialMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 29, 2024 | markets.businessinsider.comAcrivon Therapeutics: Strong Buy on Promising Clinical Trials and Innovative Drug DevelopmentMarch 28, 2024 | investorplace.comACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023March 28, 2024 | finanznachrichten.deAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 28, 2024 | benzinga.comAcrivon Therapeutics: Q4 Earnings InsightsMarch 28, 2024 | globenewswire.comAcrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 26, 2024 | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Rating of "Buy" by AnalystsMarch 5, 2024 | globenewswire.comAcrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316March 4, 2024 | finance.yahoo.comAcrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of DirectorsMarch 2, 2024 | msn.comJMP Securities Initiates Coverage of Acrivon Therapeutics (ACRV) with Market Outperform RecommendationMarch 1, 2024 | markets.businessinsider.comUnlocking Value in Precision Oncology: Acrivon Therapeutics’ Unique Platform and Promising PipelineFebruary 27, 2024 | globenewswire.comAcrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care ConferenceFebruary 9, 2024 | msn.comAcrivon Therapeutics Welcomes New Board Member Dr. Magovcevic-LiebischFebruary 8, 2024 | finance.yahoo.comAcrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of DirectorsFebruary 6, 2024 | finance.yahoo.comAcrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 4, 2024 | finance.yahoo.comAcrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2024 | msn.comAcrivon Therapeutics appoints Jean-Marie Cuillerot as Chief Medical OfficerJanuary 3, 2024 | finance.yahoo.comAcrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical OfficerDecember 5, 2023 | msn.comTravere Therapeutics, Replimune among healthcare moversDecember 1, 2023 | msn.comAcrivon Therapeutics files for $300M mixed shelfNovember 28, 2023 | markets.businessinsider.comAcrivon Announces Breakthrough Device Designation For ACR-368 OncoSignature AssayNovember 28, 2023 | marketwatch.comAcrivon Therapeutics Gets FDA's Breakthrough Designation for Cancer AssayNovember 28, 2023 | markets.businessinsider.comAcrivon Gets FDA's Breakthrough Device Designation For ACR-368 OncoSignature AssayNovember 11, 2023 | benzinga.comAcrivon Therapeutics Stock (NASDAQ:ACRV), Analyst Ratings, Price Targets, PredictionsSee More Headlines Receive ACRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2023Today3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACRV CUSIPN/A CIK1781174 Webwww.acrivon.com Phone617-207-8979FaxN/AEmployees56Year FoundedN/APrice Target and Rating Average Stock Price Target$22.14 High Stock Price Target$26.00 Low Stock Price Target$14.00 Potential Upside/Downside+209.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.39% Return on Assets-30.23% Debt Debt-to-Equity RatioN/A Current Ratio15.54 Quick Ratio15.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.16 per share Price / Book0.88Miscellaneous Outstanding Shares22,190,000Free Float20,574,000Market Cap$158.66 million OptionableNot Optionable Beta1.70 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Peter Blume-Jensen M.D. (Age 61)Ph.D., Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer Comp: $1.01MMs. Kristina Masson M.B.A. (Age 43)Ph.D., Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director Mr. Rasmus Holm-Jorgensen (Age 53)Chief Financial Officer Comp: $1MDr. Eric J. Devroe Ph.D. (Age 46)Chief Operating Officer Comp: $614.78kMs. Katharine Peterson CPAVice President of Finance & AccountingDr. Adam D. Levy M.B.A.Ph.D., Senior VP and Head of Investor Relations & Corporate AffairsMr. Bruce CloseVice President of Quality & ComplianceMs. Mary-Alice Miller J.D. (Age 50)Chief Legal Officer Ms. Parvin MiahVP & Head of Human ResourcesDr. Erick Gamelin M.D. (Age 66)Ph.D., Chief Development Officer Comp: $480.72kMore ExecutivesKey CompetitorsBeyondSpringNASDAQ:BYSIRelmada TherapeuticsNASDAQ:RLMDPDS BiotechnologyNASDAQ:PDSBCytomX TherapeuticsNASDAQ:CTMXGalectin TherapeuticsNASDAQ:GALTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 7,570 shares on 3/11/2024Ownership: 2.145%Vanguard Group Inc.Bought 7,570 shares on 2/15/2024Ownership: 2.145%Bridgeway Capital Management LLCBought 31,981 shares on 2/15/2024Ownership: 0.144%Barclays PLCBought 10,384 shares on 2/15/2024Ownership: 0.110%Northern Trust CorpBought 7,427 shares on 2/13/2024Ownership: 0.361%View All Insider TransactionsView All Institutional Transactions ACRV Stock Analysis - Frequently Asked Questions Should I buy or sell Acrivon Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acrivon Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACRV shares. View ACRV analyst ratings or view top-rated stocks. What is Acrivon Therapeutics' stock price target for 2024? 6 brokerages have issued 12-month price targets for Acrivon Therapeutics' shares. Their ACRV share price targets range from $14.00 to $26.00. On average, they predict the company's share price to reach $22.14 in the next year. This suggests a possible upside of 209.7% from the stock's current price. View analysts price targets for ACRV or view top-rated stocks among Wall Street analysts. How have ACRV shares performed in 2024? Acrivon Therapeutics' stock was trading at $4.92 at the beginning of 2024. Since then, ACRV stock has increased by 45.3% and is now trading at $7.15. View the best growth stocks for 2024 here. Are investors shorting Acrivon Therapeutics? Acrivon Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 484,000 shares, an increase of 22.7% from the February 29th total of 394,600 shares. Based on an average daily volume of 72,000 shares, the days-to-cover ratio is currently 6.7 days. Approximately 4.0% of the company's stock are short sold. View Acrivon Therapeutics' Short Interest. How were Acrivon Therapeutics' earnings last quarter? Acrivon Therapeutics, Inc. (NASDAQ:ACRV) released its quarterly earnings data on Friday, August, 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.02. What ETF holds Acrivon Therapeutics' stock? Range Cancer Therapeutics ETF holds 10,409 shares of ACRV stock, representing 1.23% of its portfolio. When did Acrivon Therapeutics IPO? Acrivon Therapeutics (ACRV) raised $100 million in an initial public offering (IPO) on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO. Who are Acrivon Therapeutics' major shareholders? Acrivon Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.15%), Vanguard Group Inc. (2.14%), Northern Trust Corp (0.36%), Bridgeway Capital Management LLC (0.14%), Barclays PLC (0.11%) and Exchange Traded Concepts LLC (0.06%). Insiders that own company stock include Ltd Chione and Ra Capital Management, LP. View institutional ownership trends. How do I buy shares of Acrivon Therapeutics? Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACRV) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.